RECRUITINGOBSERVATIONAL
Psychiatric Multi-omics and Neuroimaging Project
Psychiatric Multi-omics and Neuroimaging Project Database
About This Trial
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
- Course of disease: \<24 months
- Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks
- No nuclear magnetic contraindications.
Who Should NOT Join This Trial:
- Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
- Have a major physical disease or infectious disease
- History of coma and serious neurological disease 4.MRI contraindications.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
* Course of disease: \<24 months
* Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks
* No nuclear magnetic contraindications.
Exclusion Criteria:
* Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
* Have a major physical disease or infectious disease
* History of coma and serious neurological disease 4.MRI contraindications.
Treatments Being Tested
DRUG
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Locations (1)
The Second Xiangya hospital of central south univerity
Changsha, Hunan, China